Malignant Mesothelioma Market
Malignant Mesothelioma Market Study by Pemetrexed & Combination, Cisplatin & Combination, Carboplatin & Combination, Gemcitabine & Combination, and Other Drugs from 2024 to 2034
Analysis of Malignant Mesothelioma Market Covering 30+ Countries Including Analysis of US, Canada, UK, Germany, France, Nordics, GCC countries, Japan, Korea and many more
Malignant Mesothelioma Market Outlook (2024 to 2034)
The global malignant mesothelioma market size is estimated to be valued at US$ 561.9 million in 2024. The market is projected to register a promising CAGR of 7.6% to accumulate sales worth US$ 1,164.9 million by 2034.
Key players providing malignant mesothelioma therapeutics are expected to deploy tools like artificial intelligence, 3D printing, and nanotechnology for improved production efficiency. Thereby meeting the increasing demand for drugs/ medications to raise the patient's life expectancy.
Leading companies are also taking significant steps to develop novel products that offer improved efficacy and results. Thus increasing their reliability and preference among healthcare practitioners.
Factors Uplifting the Growth of Malignant Mesothelioma Market
Surging consumption habits related to tobacco and cigarettes, to reduce stress levels or for other purposes, have been observed as a primary factor behind increasing cases of malignant mesothelioma. People are becoming concerned for their health as the prevalence of malignant mesothelioma continues to escalate. Out of worry, people are taking precautions and diagnosis for early disease detection. Moreover, rising approvals for effective combined therapy are expected to favor malignant mesothelioma therapeutics.
Numerous active players are working in association with other organizations to discover the effects of combining several medications on malignant mesothelioma. Further, various firms are executing clinical studies concentrating on different combination medications owing to a lack of technique patents.
| Report Attributes | Details |
|---|---|
| Estimated Market Value (2024E) | US$ 561.9 million |
| Forecasted Market Value (2034F) | US$ 1,164.9 million |
| Projected Growth Rate (2024 to 2034) | 7.6%CAGR |
| Pemetrexed and Combination Segment Growth Rate (2024 to 2034) | 7.8% CAGR |
| Parental Segment Growth Rate (2024 to 2034) | 7.6% CAGR |
| North America Market Share (2024) | 37% |
| Latin America Market Share (2024) | 11.9% |
| Key Companies Profiled in the Malignant Mesothelioma Industry Report |
|
Don't Need a Global Report?
save 40%! on Country & Region specific reports
Which Trends Dictate the Malignant Mesothelioma Market?
“Increasing Research and Development Activities is Enhancing the Market Scope of Malignant Mesothelioma”
Leading firms are extensively investing in research and development activities to launch targeted therapies that focus on particular molecules or pathways engaged in the development and proliferation of cancer cells. Consequently, developing a positive outlook for malignant mesothelioma therapeutics. The launch of high-resolution CT scanning to detect abnormalities in certain body parts is also giving momentum to market expansion.
What are the Main Challenges that are Restricting the Market’s Growth?
“Unfavorable Aspects of Malignant Mesothelioma Drugs Like High Cost and Low Survival Rate”
Drugs prescribed for the treatment of malignant mesothelioma are heavy on pockets. This restricts its uptake in countries where income levels are average, and prospects for additional expenses are dim. In addition to this, the low survival rate offered by these drugs, which is usually five years or less, is also limiting the consumption of drugs intended for malignant mesothelioma.
More Insights, Lesser Cost (-50% off)
Insights on import/export production,
pricing analysis, and more – Only @ Fact.MR
Region-wise Insights
Which Region Captures Substantial Market Share in the Following Years?
“North America’s Share in the Market is Prominently High”
As per the recent market estimates, the North America malignant mesothelioma market is expected to acquire a massive value share of 37% in 2024. Revenue generated by this regional market is forecast to rise from US$ 208 million in 2024 to US$ 389 million by 2034. Demand for malignant mesothelioma therapeutics is projected to register a 6.5% CAGR during this period.
Growth in North America is expected to be driven by rising knowledge about drug and diagnostic procedures. Increasing cases of malignant mesothelioma and the rising availability of treatment options for people suffering from this disease are key factors that are driving the market forward.
Which Region is Expected to Register Higher Growth Rate?
“Latin America is Anticipated to Exhibit Promising Growth Potential in the Upcoming Years”
According to recent market predictions, the Latin America market for malignant mesothelioma is expected to obtain a small share of 11.9% in 2024. The adoption rate for malignant mesothelioma therapeutics, however, is expected to witness intensified growth. Through 2034, this regional market is projected to record a 9.4% CAGR.
Rising prevalence of cancer and surging cognizance about present cancer treatment methods are anticipated to drive up the market demand. The development of advanced therapies is further expected to elevate the market’s scope.
Country-wise Insights
Which Country in North America Dominates the Regional Sphere?
“The United States is Forecast to Lead with a Share of 68.1% in North America”
The United States malignant mesothelioma market is estimated to attain US$ 141 million in 2024. With a projected CAGR of 6.4%, the market is forecast to attain a valuation of US$ 264 million by 2034.
The expansion of malignant mesothelioma industry in the United States is backed by an increasing count of leading players as well as rising spending on research and development. Additionally, significant investments in the healthcare sector and the availability of expert doctors are boosting medical tourism in the country. Thus surging the prospects for malignant mesothelioma industry players.
Which Country is Anticipated to Accelerate at a Promising Pace?
“Chile is Expected to Observe Flourishing Growth Rate”
Chile is expected to register a CAGR of 9.5% over the forecast period. The country is witnessing a significant rise in cases of malignant mesothelioma, which is creating a heightened demand for malignant mesothelioma therapeutics. Chile is expected to occupy a 65.3% share of Latin America in 2024. In the same year, the country is estimated to capture a market value of US$ 44 million.
Know thy Competitors
Competitive landscape highlights only certain players
Complete list available upon request
Segment-wise Insights
Which Drug Type Captures a Considerable Market Share?
“Pemetrexed and Combination Gains a Leading Position in the Malignant Mesothelioma Market”
The pemetrexed and combination drug type enjoys a leading stance, occupying a share of 49.8% in 2024. Sales of pemetrexed and combination drugs are estimated to generate a revenue of US$ 280.0 million in 2024. Recording a purchase rate of 7.8% CAGR, pemetrexed and combination drugs are forecast to attain US$ 596.0 million by 2034. This segment’s growth hinges on the rising clinical trials by key players and related organizations to discover more effective pemetrexed and combination drugs.
Which Route of Administration is Highly Preferred?
“Parenteral Route of Administration is Substantially Preferred by Patients and Medical Professionals Alike”
The parenteral route of administration is expected to obtain a value share of 92.2% in 2024. Sales generated by this administration mode are estimated to be US$ 518.2 million in 2024. By 2034, the segment is forecast to attain US$ 1,075.7 million on the back of a 7.6% CAGR.
Increasing concerns over the full absorption of drugs and sufficient drug delivery to the tumor site are propelling the demand for the parenteral segment. This route of administration ensures a stronger therapeutic effect in comparison to oral medications.
Which Distribution Channel is Sought Frequently for Malignant Mesothelioma Medications?
“Individuals Prefer Purchasing Medications for Malignant Mesothelioma from Hospital Pharmacies”
The hospital pharmacy segment is expected to capture a dominant market share of 51.3% in 2024. The segment is estimated to be valued at US$ 288.4 million in 2024, and for 2034, it is forecast to reach US$ 618.4 million. In the meantime, the segment growth is projected to be 7.9% CAGR. Growing drug purchases for malignant mesothelioma from hospital pharmacies, due to their accessibility, is appreciating this segment’s value.
Competitive Landscape
Key players in the malignant mesothelioma market are investing in research and development activities for novel mesothelioma treatments, such as immunotherapy drugs, targeted therapies, and combination therapies, to provide significant benefits. Additionally, market leaders are optimizing their present drugs via formulations to reduce their side effects, improve their efficacy, and develop better delivery systems for effective differentiation.
Industry participants are creating and commercializing advanced diagnostic tools to detect malignant mesothelioma to enhance patient outcomes and market size. In tandem with this, players are charting new territories where the incidence rate for this disease is rising. Presently, markets in focus are Latin America and Asia Pacific, in addition to established markets.
Market contenders are also collaborating with patient advocacy groups, research institutions, and other healthcare providers to expand their reach, improve brand image, and increase research efficiency. Acquisitions and mergers with smaller or same-sized companies are also facilitating market consolidation.
Recent Developments in the Malignant Mesothelioma Market
- In June 2023, Amneal Pharmaceuticals, Inc. announced that it had received 505(b)(2) New Drug Application (NDA) permission from the United States FDA. This product is the first and single ready-to-use demonstration of pemetrexed for injection and requires no dilution, reconstitution, or refrigeration. This injectable is used to treat malignant pleural mesothelioma and non-squamous non-small cell lung cancer.
- In May 2023, researchers concluded that quinacrine, which is an antimalarial drug when applied to mesothelioma cells, can safeguard intense tumors from developing new blood vessels and causing cell death.
- In April 2023, the FDA presented fast-track designation to SynKIR-110, a novel T-Cell therapy, for the treatment of patients suffering from mesothelioma. It is an important milestone for the company as it acknowledges the efforts made by the firm to bring this life-saving drug to patients requiring new treatment options.
- In October 2020, the FDA granted permission to Opdivo (nivolumab) combined with Yervoy (ipilimumab) to treat mesothelioma. This drug combination is used as first-line treatment for adults suffering from malignant pleural mesothelioma. In 16 years, this is the first drug regimen which has been permitted for mesothelioma.
Segmentation of Malignant Mesothelioma Market Research
-
By Drug Type:
- Pemetrexed and combination
- Cisplatin and combination
- Carboplatin and combination
- Gemcitabine and combination
- Vinorelbine and combination
- Others combinations
-
By Route of Administration:
- Oral
- Parenteral
-
By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Oncology Centers
-
By Region:
- North America
- Europe
- Latin America
- East Asia
- South Asia and Oceania
- The Middle East and Africa
Table of Content
1. Executive Summary 1.1. Global Market Outlook 1.2. Demand-side Trends 1.3. Supply-side Trends 1.4. Technology Roadmap Analysis 1.5. Analysis and Recommendations 2. Market Overview 2.1. Market Coverage / Taxonomy 2.2. Market Definition / Scope / Limitations 3. Market Background 3.1. Market Dynamics 3.1.1. Drivers 3.1.2. Restraints 3.1.3. Opportunity 3.1.4. Trends 3.2. Scenario Forecast 3.2.1. Demand in Optimistic Scenario 3.2.2. Demand in Likely Scenario 3.2.3. Demand in Conservative Scenario 3.3. Opportunity Map Analysis 3.4. Product Life Cycle Analysis 3.5. Supply Chain Analysis 3.5.1. Supply Side Participants and their Roles 3.5.1.1. Producers 3.5.1.2. Mid-Level Participants (Traders/ Agents/ Brokers) 3.5.1.3. Wholesalers and Distributors 3.5.2. Value Added and Value Created at Node in the Supply Chain 3.5.3. List of Raw Material Suppliers 3.5.4. List of Existing and Potential Buyer’s 3.6. Investment Feasibility Matrix 3.7. Value Chain Analysis 3.7.1. Profit Margin Analysis 3.7.2. Wholesalers and Distributors 3.7.3. Retailers 3.8. PESTLE and Porter’s Analysis 3.9. Regulatory Landscape 3.9.1. By Key Regions 3.9.2. By Key Countries 3.10. Regional Parent Market Outlook 3.11. Production and Consumption Statistics 3.12. Import and Export Statistics 4. Global Market Analysis 2019-2023 and Forecast, 2024-2034 4.1. Historical Market Size Value (US$ Mn) & Volume (Units Pack) Analysis, 2019-2023 4.2. Current and Future Market Size Value (US$ Mn) & Volume (Units Pack) Projections, 2024-2034 4.2.1. Y-o-Y Growth Trend Analysis 4.2.2. Absolute $ Opportunity Analysis 5. Global Market Analysis 2019-2023 and Forecast 2024-2034, By Drug Type 5.1. Introduction / Key Findings 5.2. Historical Market Size Value (US$ Mn) & Volume (Units Pack) Analysis By Drug Type, 2019-2023 5.3. Current and Future Market Size Value (US$ Mn) & Volume (Units Pack) Analysis and Forecast By Drug Type, 2024-2034 5.3.1. Pemetrexed 5.3.2. Cisplatin 5.3.3. Carboplatin 5.3.4. Gemcitabine 5.3.5. Vinorelbine 5.3.6. Others 5.4. Y-o-Y Growth Trend Analysis By Drug Type, 2019-2023 5.5. Absolute $ Opportunity Analysis By Drug Type, 2024-2034 6. Global Market Analysis 2019-2023 and Forecast 2024-2034, By Route of Administration 6.1. Introduction / Key Findings 6.2. Historical Market Size Value (US$ Mn) & Volume (Units Pack) Analysis By Route of Administration, 2019-2023 6.3. Current and Future Market Size Value (US$ Mn) & Volume (Units Pack) Analysis and Forecast By Route of Administration, 2024-2034 6.3.1. Oral 6.3.2. Parenteral 6.4. Y-o-Y Growth Trend Analysis By Route of Administration, 2019-2023 6.5. Absolute $ Opportunity Analysis By Route of Administration, 2024-2034 7. Global Market Analysis 2019-2023 and Forecast 2024-2034, By Region 7.1. Introduction 7.2. Historical Market Size Value (US$ Mn) & Volume (Units Pack) Analysis By Region, 2019-2023 7.3. Current Market Size Value (US$ Mn) & Volume (Units Pack) Analysis and Forecast By Region, 2024-2034 7.3.1. North America 7.3.2. Latin America 7.3.3. Western Europe 7.3.4. Eastern Europe 7.3.5. South Asia and Pacific 7.3.6. East Asia 7.3.7. Middle East and Africa 7.4. Market Attractiveness Analysis By Region 8. North America Market Analysis 2019-2023 and Forecast 2024-2034, By Country 8.1. Historical Market Size Value (US$ Mn) & Volume (Units Pack) Trend Analysis By Market Taxonomy, 2019-2023 8.2. Market Size Value (US$ Mn) & Volume (Units Pack) Forecast By Market Taxonomy, 2024-2034 8.2.1. By Country 8.2.1.1. U.S. 8.2.1.2. Canada 8.2.2. By Drug Type 8.2.3. By Route of Administration 8.3. Market Attractiveness Analysis 8.3.1. By Country 8.3.2. By Drug Type 8.3.3. By Route of Administration 8.4. Key Takeaways 9. Latin America Market Analysis 2019-2023 and Forecast 2024-2034, By Country 9.1. Historical Market Size Value (US$ Mn) & Volume (Units Pack) Trend Analysis By Market Taxonomy, 2019-2023 9.2. Market Size Value (US$ Mn) & Volume (Units Pack) Forecast By Market Taxonomy, 2024-2034 9.2.1. By Country 9.2.1.1. Brazil 9.2.1.2. Mexico 9.2.1.3. Rest of Latin America 9.2.2. By Drug Type 9.2.3. By Route of Administration 9.3. Market Attractiveness Analysis 9.3.1. By Country 9.3.2. By Drug Type 9.3.3. By Route of Administration 9.4. Key Takeaways 10. Western Europe Market Analysis 2019-2023 and Forecast 2024-2034, By Country 10.1. Historical Market Size Value (US$ Mn) & Volume (Units Pack) Trend Analysis By Market Taxonomy, 2019-2023 10.2. Market Size Value (US$ Mn) & Volume (Units Pack) Forecast By Market Taxonomy, 2024-2034 10.2.1. By Country 10.2.1.1. Germany 10.2.1.2. U.K. 10.2.1.3. France 10.2.1.4. Spain 10.2.1.5. Italy 10.2.1.6. Rest of Western Europe 10.2.2. By Drug Type 10.2.3. By Route of Administration 10.3. Market Attractiveness Analysis 10.3.1. By Country 10.3.2. By Drug Type 10.3.3. By Route of Administration 10.4. Key Takeaways 11. Eastern Europe Market Analysis 2019-2023 and Forecast 2024-2034, By Country 11.1. Historical Market Size Value (US$ Mn) & Volume (Units Pack) Trend Analysis By Market Taxonomy, 2019-2023 11.2. Market Size Value (US$ Mn) & Volume (Units Pack) Forecast By Market Taxonomy, 2024-2034 11.2.1. By Country 11.2.1.1. Poland 11.2.1.2. Russia 11.2.1.3. Czech Republic 11.2.1.4. Romania 11.2.1.5. Rest of Eastern Europe 11.2.2. By Drug Type 11.2.3. By Route of Administration 11.3. Market Attractiveness Analysis 11.3.1. By Country 11.3.2. By Drug Type 11.3.3. By Route of Administration 11.4. Key Takeaways 12. South Asia and Pacific Market Analysis 2019-2023 and Forecast 2024-2034, By Country 12.1. Historical Market Size Value (US$ Mn) & Volume (Units Pack) Trend Analysis By Market Taxonomy, 2019-2023 12.2. Market Size Value (US$ Mn) & Volume (Units Pack) Forecast By Market Taxonomy, 2024-2034 12.2.1. By Country 12.2.1.1. India 12.2.1.2. Bangladesh 12.2.1.3. Australia 12.2.1.4. New Zealand 12.2.1.5. Rest of South Asia and Pacific 12.2.2. By Drug Type 12.2.3. By Route of Administration 12.3. Market Attractiveness Analysis 12.3.1. By Country 12.3.2. By Drug Type 12.3.3. By Route of Administration 12.4. Key Takeaways 13. East Asia Market Analysis 2019-2023 and Forecast 2024-2034, By Country 13.1. Historical Market Size Value (US$ Mn) & Volume (Units Pack) Trend Analysis By Market Taxonomy, 2019-2023 13.2. Market Size Value (US$ Mn) & Volume (Units Pack) Forecast By Market Taxonomy, 2024-2034 13.2.1. By Country 13.2.1.1. China 13.2.1.2. Japan 13.2.1.3. South Korea 13.2.2. By Drug Type 13.2.3. By Route of Administration 13.3. Market Attractiveness Analysis 13.3.1. By Country 13.3.2. By Drug Type 13.3.3. By Route of Administration 13.4. Key Takeaways 14. Middle East and Africa Market Analysis 2019-2023 and Forecast 2024-2034, By Country 14.1. Historical Market Size Value (US$ Mn) & Volume (Units Pack) Trend Analysis By Market Taxonomy, 2019-2023 14.2. Market Size Value (US$ Mn) & Volume (Units Pack) Forecast By Market Taxonomy, 2024-2034 14.2.1. By Country 14.2.1.1. GCC Countries 14.2.1.2. South Africa 14.2.1.3. Israel 14.2.1.4. Rest of MEA 14.2.2. By Drug Type 14.2.3. By Route of Administration 14.3. Market Attractiveness Analysis 14.3.1. By Country 14.3.2. By Drug Type 14.3.3. By Route of Administration 14.4. Key Takeaways 15. Key Countries Market Analysis 15.1. U.S. 15.1.1. Pricing Analysis 15.1.2. Market Share Analysis, 2023 15.1.2.1. By Drug Type 15.1.2.2. By Route of Administration 15.2. Canada 15.2.1. Pricing Analysis 15.2.2. Market Share Analysis, 2023 15.2.2.1. By Drug Type 15.2.2.2. By Route of Administration 15.3. Brazil 15.3.1. Pricing Analysis 15.3.2. Market Share Analysis, 2023 15.3.2.1. By Drug Type 15.3.2.2. By Route of Administration 15.4. Mexico 15.4.1. Pricing Analysis 15.4.2. Market Share Analysis, 2023 15.4.2.1. By Drug Type 15.4.2.2. By Route of Administration 15.5. Germany 15.5.1. Pricing Analysis 15.5.2. Market Share Analysis, 2023 15.5.2.1. By Drug Type 15.5.2.2. By Route of Administration 15.6. U.K. 15.6.1. Pricing Analysis 15.6.2. Market Share Analysis, 2023 15.6.2.1. By Drug Type 15.6.2.2. By Route of Administration 15.7. France 15.7.1. Pricing Analysis 15.7.2. Market Share Analysis, 2023 15.7.2.1. By Drug Type 15.7.2.2. By Route of Administration 15.8. Spain 15.8.1. Pricing Analysis 15.8.2. Market Share Analysis, 2023 15.8.2.1. By Drug Type 15.8.2.2. By Route of Administration 15.9. Italy 15.9.1. Pricing Analysis 15.9.2. Market Share Analysis, 2023 15.9.2.1. By Drug Type 15.9.2.2. By Route of Administration 15.10. Poland 15.10.1. Pricing Analysis 15.10.2. Market Share Analysis, 2023 15.10.2.1. By Drug Type 15.10.2.2. By Route of Administration 15.11. Russia 15.11.1. Pricing Analysis 15.11.2. Market Share Analysis, 2023 15.11.2.1. By Drug Type 15.11.2.2. By Route of Administration 15.12. Czech Republic 15.12.1. Pricing Analysis 15.12.2. Market Share Analysis, 2023 15.12.2.1. By Drug Type 15.12.2.2. By Route of Administration 15.13. Romania 15.13.1. Pricing Analysis 15.13.2. Market Share Analysis, 2023 15.13.2.1. By Drug Type 15.13.2.2. By Route of Administration 15.14. India 15.14.1. Pricing Analysis 15.14.2. Market Share Analysis, 2023 15.14.2.1. By Drug Type 15.14.2.2. By Route of Administration 15.15. Bangladesh 15.15.1. Pricing Analysis 15.15.2. Market Share Analysis, 2023 15.15.2.1. By Drug Type 15.15.2.2. By Route of Administration 15.16. Australia 15.16.1. Pricing Analysis 15.16.2. Market Share Analysis, 2023 15.16.2.1. By Drug Type 15.16.2.2. By Route of Administration 15.17. New Zealand 15.17.1. Pricing Analysis 15.17.2. Market Share Analysis, 2023 15.17.2.1. By Drug Type 15.17.2.2. By Route of Administration 15.18. China 15.18.1. Pricing Analysis 15.18.2. Market Share Analysis, 2023 15.18.2.1. By Drug Type 15.18.2.2. By Route of Administration 15.19. Japan 15.19.1. Pricing Analysis 15.19.2. Market Share Analysis, 2023 15.19.2.1. By Drug Type 15.19.2.2. By Route of Administration 15.20. South Korea 15.20.1. Pricing Analysis 15.20.2. Market Share Analysis, 2023 15.20.2.1. By Drug Type 15.20.2.2. By Route of Administration 15.21. GCC Countries 15.21.1. Pricing Analysis 15.21.2. Market Share Analysis, 2023 15.21.2.1. By Drug Type 15.21.2.2. By Route of Administration 15.22. South Africa 15.22.1. Pricing Analysis 15.22.2. Market Share Analysis, 2023 15.22.2.1. By Drug Type 15.22.2.2. By Route of Administration 15.23. Israel 15.23.1. Pricing Analysis 15.23.2. Market Share Analysis, 2023 15.23.2.1. By Drug Type 15.23.2.2. By Route of Administration 16. Market Structure Analysis 16.1. Competition Dashboard 16.2. Competition Benchmarking 16.3. Market Share Analysis of Top Players 16.3.1. By Regional 16.3.2. By Drug Type 16.3.3. By Route of Administration 17. Competition Analysis 17.1. Competition Deep Dive 17.1.1. Merck & Co., Inc. 17.1.1.1. Overview 17.1.1.2. Product Portfolio 17.1.1.3. Profitability by Market Segments 17.1.1.4. Sales Footprint 17.1.1.5. Strategy Overview 17.1.1.5.1. Marketing Strategy 17.1.1.5.2. Product Strategy 17.1.1.5.3. Channel Strategy 17.1.2. Novartis AG 17.1.2.1. Overview 17.1.2.2. Product Portfolio 17.1.2.3. Profitability by Market Segments 17.1.2.4. Sales Footprint 17.1.2.5. Strategy Overview 17.1.2.5.1. Marketing Strategy 17.1.2.5.2. Product Strategy 17.1.2.5.3. Channel Strategy 17.1.3. Pfizer Inc. 17.1.3.1. Overview 17.1.3.2. Product Portfolio 17.1.3.3. Profitability by Market Segments 17.1.3.4. Sales Footprint 17.1.3.5. Strategy Overview 17.1.3.5.1. Marketing Strategy 17.1.3.5.2. Product Strategy 17.1.3.5.3. Channel Strategy 17.1.4. Sanofi 17.1.4.1. Overview 17.1.4.2. Product Portfolio 17.1.4.3. Profitability by Market Segments 17.1.4.4. Sales Footprint 17.1.4.5. Strategy Overview 17.1.4.5.1. Marketing Strategy 17.1.4.5.2. Product Strategy 17.1.4.5.3. Channel Strategy 17.1.5. Eli Lilly and Company 17.1.5.1. Overview 17.1.5.2. Product Portfolio 17.1.5.3. Profitability by Market Segments 17.1.5.4. Sales Footprint 17.1.5.5. Strategy Overview 17.1.5.5.1. Marketing Strategy 17.1.5.5.2. Product Strategy 17.1.5.5.3. Channel Strategy 17.1.6. Teva Pharmaceuticals 17.1.6.1. Overview 17.1.6.2. Product Portfolio 17.1.6.3. Profitability by Market Segments 17.1.6.4. Sales Footprint 17.1.6.5. Strategy Overview 17.1.6.5.1. Marketing Strategy 17.1.6.5.2. Product Strategy 17.1.6.5.3. Channel Strategy 17.1.7. Sun Pharmaceuticals Industries Ltd 17.1.7.1. Overview 17.1.7.2. Product Portfolio 17.1.7.3. Profitability by Market Segments 17.1.7.4. Sales Footprint 17.1.7.5. Strategy Overview 17.1.7.5.1. Marketing Strategy 17.1.7.5.2. Product Strategy 17.1.7.5.3. Channel Strategy 17.1.8. Corden Pharma International GmbH 17.1.8.1. Overview 17.1.8.2. Product Portfolio 17.1.8.3. Profitability by Market Segments 17.1.8.4. Sales Footprint 17.1.8.5. Strategy Overview 17.1.8.5.1. Marketing Strategy 17.1.8.5.2. Product Strategy 17.1.8.5.3. Channel Strategy 17.1.9. Concordia International Corp 17.1.9.1. Overview 17.1.9.2. Product Portfolio 17.1.9.3. Profitability by Market Segments 17.1.9.4. Sales Footprint 17.1.9.5. Strategy Overview 17.1.9.5.1. Marketing Strategy 17.1.9.5.2. Product Strategy 17.1.9.5.3. Channel Strategy 17.1.10. Polaris Pharmaceuticals, Inc 17.1.10.1. Overview 17.1.10.2. Product Portfolio 17.1.10.3. Profitability by Market Segments 17.1.10.4. Sales Footprint 17.1.10.5. Strategy Overview 17.1.10.5.1. Marketing Strategy 17.1.10.5.2. Product Strategy 17.1.10.5.3. Channel Strategy 18. Assumptions & Acronyms Used 19. Research Methodology
Don't Need a Global Report?
save 40%! on Country & Region specific reports
List Of Table
Table 1: Global Market Value (US$ Mn) Forecast by Region, 2019-2034
Table 2: Global Market Volume (Units Pack) Forecast by Region, 2019-2034
Table 3: Global Market Value (US$ Mn) Forecast by Drug Type, 2019-2034
Table 4: Global Market Volume (Units Pack) Forecast by Drug Type, 2019-2034
Table 5: Global Market Value (US$ Mn) Forecast by Route of Administration, 2019-2034
Table 6: Global Market Volume (Units Pack) Forecast by Route of Administration, 2019-2034
Table 7: North America Market Value (US$ Mn) Forecast by Country, 2019-2034
Table 8: North America Market Volume (Units Pack) Forecast by Country, 2019-2034
Table 9: North America Market Value (US$ Mn) Forecast by Drug Type, 2019-2034
Table 10: North America Market Volume (Units Pack) Forecast by Drug Type, 2019-2034
Table 11: North America Market Value (US$ Mn) Forecast by Route of Administration, 2019-2034
Table 12: North America Market Volume (Units Pack) Forecast by Route of Administration, 2019-2034
Table 13: Latin America Market Value (US$ Mn) Forecast by Country, 2019-2034
Table 14: Latin America Market Volume (Units Pack) Forecast by Country, 2019-2034
Table 15: Latin America Market Value (US$ Mn) Forecast by Drug Type, 2019-2034
Table 16: Latin America Market Volume (Units Pack) Forecast by Drug Type, 2019-2034
Table 17: Latin America Market Value (US$ Mn) Forecast by Route of Administration, 2019-2034
Table 18: Latin America Market Volume (Units Pack) Forecast by Route of Administration, 2019-2034
Table 19: Western Europe Market Value (US$ Mn) Forecast by Country, 2019-2034
Table 20: Western Europe Market Volume (Units Pack) Forecast by Country, 2019-2034
Table 21: Western Europe Market Value (US$ Mn) Forecast by Drug Type, 2019-2034
Table 22: Western Europe Market Volume (Units Pack) Forecast by Drug Type, 2019-2034
Table 23: Western Europe Market Value (US$ Mn) Forecast by Route of Administration, 2019-2034
Table 24: Western Europe Market Volume (Units Pack) Forecast by Route of Administration, 2019-2034
Table 25: Eastern Europe Market Value (US$ Mn) Forecast by Country, 2019-2034
Table 26: Eastern Europe Market Volume (Units Pack) Forecast by Country, 2019-2034
Table 27: Eastern Europe Market Value (US$ Mn) Forecast by Drug Type, 2019-2034
Table 28: Eastern Europe Market Volume (Units Pack) Forecast by Drug Type, 2019-2034
Table 29: Eastern Europe Market Value (US$ Mn) Forecast by Route of Administration, 2019-2034
Table 30: Eastern Europe Market Volume (Units Pack) Forecast by Route of Administration, 2019-2034
Table 31: South Asia and Pacific Market Value (US$ Mn) Forecast by Country, 2019-2034
Table 32: South Asia and Pacific Market Volume (Units Pack) Forecast by Country, 2019-2034
Table 33: South Asia and Pacific Market Value (US$ Mn) Forecast by Drug Type, 2019-2034
Table 34: South Asia and Pacific Market Volume (Units Pack) Forecast by Drug Type, 2019-2034
Table 35: South Asia and Pacific Market Value (US$ Mn) Forecast by Route of Administration, 2019-2034
Table 36: South Asia and Pacific Market Volume (Units Pack) Forecast by Route of Administration, 2019-2034
Table 37: East Asia Market Value (US$ Mn) Forecast by Country, 2019-2034
Table 38: East Asia Market Volume (Units Pack) Forecast by Country, 2019-2034
Table 39: East Asia Market Value (US$ Mn) Forecast by Drug Type, 2019-2034
Table 40: East Asia Market Volume (Units Pack) Forecast by Drug Type, 2019-2034
Table 41: East Asia Market Value (US$ Mn) Forecast by Route of Administration, 2019-2034
Table 42: East Asia Market Volume (Units Pack) Forecast by Route of Administration, 2019-2034
Table 43: Middle East and Africa Market Value (US$ Mn) Forecast by Country, 2019-2034
Table 44: Middle East and Africa Market Volume (Units Pack) Forecast by Country, 2019-2034
Table 45: Middle East and Africa Market Value (US$ Mn) Forecast by Drug Type, 2019-2034
Table 46: Middle East and Africa Market Volume (Units Pack) Forecast by Drug Type, 2019-2034
Table 47: Middle East and Africa Market Value (US$ Mn) Forecast by Route of Administration, 2019-2034
Table 48: Middle East and Africa Market Volume (Units Pack) Forecast by Route of Administration, 2019-2034
More Insights, Lesser Cost (-50% off)
Insights on import/export production,
pricing analysis, and more – Only @ Fact.MR
List Of Figures
Figure 1: Global Market Value (US$ Mn) by Drug Type, 2024-2034
Figure 2: Global Market Value (US$ Mn) by Route of Administration, 2024-2034
Figure 3: Global Market Value (US$ Mn) by Region, 2024-2034
Figure 4: Global Market Value (US$ Mn) Analysis by Region, 2019-2034
Figure 5: Global Market Volume (Units Pack) Analysis by Region, 2019-2034
Figure 6: Global Market Value Share (%) and BPS Analysis by Region, 2024-2034
Figure 7: Global Market Y-o-Y Growth (%) Projections by Region, 2024-2034
Figure 8: Global Market Value (US$ Mn) Analysis by Drug Type, 2019-2034
Figure 9: Global Market Volume (Units Pack) Analysis by Drug Type, 2019-2034
Figure 10: Global Market Value Share (%) and BPS Analysis by Drug Type, 2024-2034
Figure 11: Global Market Y-o-Y Growth (%) Projections by Drug Type, 2024-2034
Figure 12: Global Market Value (US$ Mn) Analysis by Route of Administration, 2019-2034
Figure 13: Global Market Volume (Units Pack) Analysis by Route of Administration, 2019-2034
Figure 14: Global Market Value Share (%) and BPS Analysis by Route of Administration, 2024-2034
Figure 15: Global Market Y-o-Y Growth (%) Projections by Route of Administration, 2024-2034
Figure 16: Global Market Attractiveness by Drug Type, 2024-2034
Figure 17: Global Market Attractiveness by Route of Administration, 2024-2034
Figure 18: Global Market Attractiveness by Region, 2024-2034
Figure 19: North America Market Value (US$ Mn) by Drug Type, 2024-2034
Figure 20: North America Market Value (US$ Mn) by Route of Administration, 2024-2034
Figure 21: North America Market Value (US$ Mn) by Country, 2024-2034
Figure 22: North America Market Value (US$ Mn) Analysis by Country, 2019-2034
Figure 23: North America Market Volume (Units Pack) Analysis by Country, 2019-2034
Figure 24: North America Market Value Share (%) and BPS Analysis by Country, 2024-2034
Figure 25: North America Market Y-o-Y Growth (%) Projections by Country, 2024-2034
Figure 26: North America Market Value (US$ Mn) Analysis by Drug Type, 2019-2034
Figure 27: North America Market Volume (Units Pack) Analysis by Drug Type, 2019-2034
Figure 28: North America Market Value Share (%) and BPS Analysis by Drug Type, 2024-2034
Figure 29: North America Market Y-o-Y Growth (%) Projections by Drug Type, 2024-2034
Figure 30: North America Market Value (US$ Mn) Analysis by Route of Administration, 2019-2034
Figure 31: North America Market Volume (Units Pack) Analysis by Route of Administration, 2019-2034
Figure 32: North America Market Value Share (%) and BPS Analysis by Route of Administration, 2024-2034
Figure 33: North America Market Y-o-Y Growth (%) Projections by Route of Administration, 2024-2034
Figure 34: North America Market Attractiveness by Drug Type, 2024-2034
Figure 35: North America Market Attractiveness by Route of Administration, 2024-2034
Figure 36: North America Market Attractiveness by Country, 2024-2034
Figure 37: Latin America Market Value (US$ Mn) by Drug Type, 2024-2034
Figure 38: Latin America Market Value (US$ Mn) by Route of Administration, 2024-2034
Figure 39: Latin America Market Value (US$ Mn) by Country, 2024-2034
Figure 40: Latin America Market Value (US$ Mn) Analysis by Country, 2019-2034
Figure 41: Latin America Market Volume (Units Pack) Analysis by Country, 2019-2034
Figure 42: Latin America Market Value Share (%) and BPS Analysis by Country, 2024-2034
Figure 43: Latin America Market Y-o-Y Growth (%) Projections by Country, 2024-2034
Figure 44: Latin America Market Value (US$ Mn) Analysis by Drug Type, 2019-2034
Figure 45: Latin America Market Volume (Units Pack) Analysis by Drug Type, 2019-2034
Figure 46: Latin America Market Value Share (%) and BPS Analysis by Drug Type, 2024-2034
Figure 47: Latin America Market Y-o-Y Growth (%) Projections by Drug Type, 2024-2034
Figure 48: Latin America Market Value (US$ Mn) Analysis by Route of Administration, 2019-2034
Figure 49: Latin America Market Volume (Units Pack) Analysis by Route of Administration, 2019-2034
Figure 50: Latin America Market Value Share (%) and BPS Analysis by Route of Administration, 2024-2034
Figure 51: Latin America Market Y-o-Y Growth (%) Projections by Route of Administration, 2024-2034
Figure 52: Latin America Market Attractiveness by Drug Type, 2024-2034
Figure 53: Latin America Market Attractiveness by Route of Administration, 2024-2034
Figure 54: Latin America Market Attractiveness by Country, 2024-2034
Figure 55: Western Europe Market Value (US$ Mn) by Drug Type, 2024-2034
Figure 56: Western Europe Market Value (US$ Mn) by Route of Administration, 2024-2034
Figure 57: Western Europe Market Value (US$ Mn) by Country, 2024-2034
Figure 58: Western Europe Market Value (US$ Mn) Analysis by Country, 2019-2034
Figure 59: Western Europe Market Volume (Units Pack) Analysis by Country, 2019-2034
Figure 60: Western Europe Market Value Share (%) and BPS Analysis by Country, 2024-2034
Figure 61: Western Europe Market Y-o-Y Growth (%) Projections by Country, 2024-2034
Figure 62: Western Europe Market Value (US$ Mn) Analysis by Drug Type, 2019-2034
Figure 63: Western Europe Market Volume (Units Pack) Analysis by Drug Type, 2019-2034
Figure 64: Western Europe Market Value Share (%) and BPS Analysis by Drug Type, 2024-2034
Figure 65: Western Europe Market Y-o-Y Growth (%) Projections by Drug Type, 2024-2034
Figure 66: Western Europe Market Value (US$ Mn) Analysis by Route of Administration, 2019-2034
Figure 67: Western Europe Market Volume (Units Pack) Analysis by Route of Administration, 2019-2034
Figure 68: Western Europe Market Value Share (%) and BPS Analysis by Route of Administration, 2024-2034
Figure 69: Western Europe Market Y-o-Y Growth (%) Projections by Route of Administration, 2024-2034
Figure 70: Western Europe Market Attractiveness by Drug Type, 2024-2034
Figure 71: Western Europe Market Attractiveness by Route of Administration, 2024-2034
Figure 72: Western Europe Market Attractiveness by Country, 2024-2034
Figure 73: Eastern Europe Market Value (US$ Mn) by Drug Type, 2024-2034
Figure 74: Eastern Europe Market Value (US$ Mn) by Route of Administration, 2024-2034
Figure 75: Eastern Europe Market Value (US$ Mn) by Country, 2024-2034
Figure 76: Eastern Europe Market Value (US$ Mn) Analysis by Country, 2019-2034
Figure 77: Eastern Europe Market Volume (Units Pack) Analysis by Country, 2019-2034
Figure 78: Eastern Europe Market Value Share (%) and BPS Analysis by Country, 2024-2034
Figure 79: Eastern Europe Market Y-o-Y Growth (%) Projections by Country, 2024-2034
Figure 80: Eastern Europe Market Value (US$ Mn) Analysis by Drug Type, 2019-2034
Figure 81: Eastern Europe Market Volume (Units Pack) Analysis by Drug Type, 2019-2034
Figure 82: Eastern Europe Market Value Share (%) and BPS Analysis by Drug Type, 2024-2034
Figure 83: Eastern Europe Market Y-o-Y Growth (%) Projections by Drug Type, 2024-2034
Figure 84: Eastern Europe Market Value (US$ Mn) Analysis by Route of Administration, 2019-2034
Figure 85: Eastern Europe Market Volume (Units Pack) Analysis by Route of Administration, 2019-2034
Figure 86: Eastern Europe Market Value Share (%) and BPS Analysis by Route of Administration, 2024-2034
Figure 87: Eastern Europe Market Y-o-Y Growth (%) Projections by Route of Administration, 2024-2034
Figure 88: Eastern Europe Market Attractiveness by Drug Type, 2024-2034
Figure 89: Eastern Europe Market Attractiveness by Route of Administration, 2024-2034
Figure 90: Eastern Europe Market Attractiveness by Country, 2024-2034
Figure 91: South Asia and Pacific Market Value (US$ Mn) by Drug Type, 2024-2034
Figure 92: South Asia and Pacific Market Value (US$ Mn) by Route of Administration, 2024-2034
Figure 93: South Asia and Pacific Market Value (US$ Mn) by Country, 2024-2034
Figure 94: South Asia and Pacific Market Value (US$ Mn) Analysis by Country, 2019-2034
Figure 95: South Asia and Pacific Market Volume (Units Pack) Analysis by Country, 2019-2034
Figure 96: South Asia and Pacific Market Value Share (%) and BPS Analysis by Country, 2024-2034
Figure 97: South Asia and Pacific Market Y-o-Y Growth (%) Projections by Country, 2024-2034
Figure 98: South Asia and Pacific Market Value (US$ Mn) Analysis by Drug Type, 2019-2034
Figure 99: South Asia and Pacific Market Volume (Units Pack) Analysis by Drug Type, 2019-2034
Figure 100: South Asia and Pacific Market Value Share (%) and BPS Analysis by Drug Type, 2024-2034
Figure 101: South Asia and Pacific Market Y-o-Y Growth (%) Projections by Drug Type, 2024-2034
Figure 102: South Asia and Pacific Market Value (US$ Mn) Analysis by Route of Administration, 2019-2034
Figure 103: South Asia and Pacific Market Volume (Units Pack) Analysis by Route of Administration, 2019-2034
Figure 104: South Asia and Pacific Market Value Share (%) and BPS Analysis by Route of Administration, 2024-2034
Figure 105: South Asia and Pacific Market Y-o-Y Growth (%) Projections by Route of Administration, 2024-2034
Figure 106: South Asia and Pacific Market Attractiveness by Drug Type, 2024-2034
Figure 107: South Asia and Pacific Market Attractiveness by Route of Administration, 2024-2034
Figure 108: South Asia and Pacific Market Attractiveness by Country, 2024-2034
Figure 109: East Asia Market Value (US$ Mn) by Drug Type, 2024-2034
Figure 110: East Asia Market Value (US$ Mn) by Route of Administration, 2024-2034
Figure 111: East Asia Market Value (US$ Mn) by Country, 2024-2034
Figure 112: East Asia Market Value (US$ Mn) Analysis by Country, 2019-2034
Figure 113: East Asia Market Volume (Units Pack) Analysis by Country, 2019-2034
Figure 114: East Asia Market Value Share (%) and BPS Analysis by Country, 2024-2034
Figure 115: East Asia Market Y-o-Y Growth (%) Projections by Country, 2024-2034
Figure 116: East Asia Market Value (US$ Mn) Analysis by Drug Type, 2019-2034
Figure 117: East Asia Market Volume (Units Pack) Analysis by Drug Type, 2019-2034
Figure 118: East Asia Market Value Share (%) and BPS Analysis by Drug Type, 2024-2034
Figure 119: East Asia Market Y-o-Y Growth (%) Projections by Drug Type, 2024-2034
Figure 120: East Asia Market Value (US$ Mn) Analysis by Route of Administration, 2019-2034
Figure 121: East Asia Market Volume (Units Pack) Analysis by Route of Administration, 2019-2034
Figure 122: East Asia Market Value Share (%) and BPS Analysis by Route of Administration, 2024-2034
Figure 123: East Asia Market Y-o-Y Growth (%) Projections by Route of Administration, 2024-2034
Figure 124: East Asia Market Attractiveness by Drug Type, 2024-2034
Figure 125: East Asia Market Attractiveness by Route of Administration, 2024-2034
Figure 126: East Asia Market Attractiveness by Country, 2024-2034
Figure 127: Middle East and Africa Market Value (US$ Mn) by Drug Type, 2024-2034
Figure 128: Middle East and Africa Market Value (US$ Mn) by Route of Administration, 2024-2034
Figure 129: Middle East and Africa Market Value (US$ Mn) by Country, 2024-2034
Figure 130: Middle East and Africa Market Value (US$ Mn) Analysis by Country, 2019-2034
Figure 131: Middle East and Africa Market Volume (Units Pack) Analysis by Country, 2019-2034
Figure 132: Middle East and Africa Market Value Share (%) and BPS Analysis by Country, 2024-2034
Figure 133: Middle East and Africa Market Y-o-Y Growth (%) Projections by Country, 2024-2034
Figure 134: Middle East and Africa Market Value (US$ Mn) Analysis by Drug Type, 2019-2034
Figure 135: Middle East and Africa Market Volume (Units Pack) Analysis by Drug Type, 2019-2034
Figure 136: Middle East and Africa Market Value Share (%) and BPS Analysis by Drug Type, 2024-2034
Figure 137: Middle East and Africa Market Y-o-Y Growth (%) Projections by Drug Type, 2024-2034
Figure 138: Middle East and Africa Market Value (US$ Mn) Analysis by Route of Administration, 2019-2034
Figure 139: Middle East and Africa Market Volume (Units Pack) Analysis by Route of Administration, 2019-2034
Figure 140: Middle East and Africa Market Value Share (%) and BPS Analysis by Route of Administration, 2024-2034
Figure 141: Middle East and Africa Market Y-o-Y Growth (%) Projections by Route of Administration, 2024-2034
Figure 142: Middle East and Africa Market Attractiveness by Drug Type, 2024-2034
Figure 143: Middle East and Africa Market Attractiveness by Route of Administration, 2024-2034
Figure 144: Middle East and Africa Market Attractiveness by Country, 2024-2034
Know thy Competitors
Competitive landscape highlights only certain players
Complete list available upon request
- FAQs -
What was the Value of the Malignant Mesothelioma Market in 2019?
The global malignant mesothelioma market was worth US$ 387.5 million in 2019.
What is the Sales Outlook for Malignant Mesothelioma in 2024?
The sales outlook for malignant mesothelioma is likely to be valued at US$ 561.9 million in 2024.
What is the Demand Forecast for Malignant Mesothelioma for the Decade?
Demand for malignant mesothelioma is forecast to reach a market value of US$ 1,164.9 million by the end of 2034
What is the Growth Projection for the Malignant Mesothelioma Market?
The market for malignant mesothelioma is projected to rise at a CAGR of 7.6% through 2034.
At What Rate Is the Market In Latin America Predicted to Grow?
The Latin America market for malignant mesothelioma is likely to expand at a CAGR of 9.4% through 2034.
Malignant Mesothelioma Market